Related references
Note: Only part of the references are listed.Identification of the Human Cytochrome P450 Enzymes Involved in the Two Oxidative Steps in the Bioactivation of Clopidogrel to Its Pharmacologically Active Metabolite
Miho Kazui et al.
DRUG METABOLISM AND DISPOSITION (2010)
Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial
Stefan James et al.
AMERICAN HEART JOURNAL (2009)
A population-based study of the drug interaction between proton pump inhibitors and clopidogrel
David N. Juurlink et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2009)
Drug Interaction Between Clopidogrel and Proton Pump Inhibitors
Saira Chand Khalique et al.
CARDIOLOGY IN REVIEW (2009)
Cytochrome P450 Genetic Polymorphisms and the Response to Prasugrel Relationship to Pharmacokinetic, Pharmacodynamic, and Clinical Outcomes
Jessica L. Mega et al.
CIRCULATION (2009)
Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease
Christoph Varenhorst et al.
EUROPEAN HEART JOURNAL (2009)
Risk of Adverse Outcomes Associated With Concomitant Use of Clopidogrel and Proton Pump Inhibitors Following Acute Coronary Syndrome
P. Michael Ho et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Comparison of Omeprazole and Pantoprazole Influence on a High 150-mg Clopidogrel Maintenance Dose The PACA (Proton Pump Inhibitors And Clopidogrel Association) Prospective Randomized Study
Thomas Cuisset et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
The CYP2C19*17 allele is associated with better platelet response to clopidogrel in patients admitted for non-ST acute coronary syndrome
C. Frere et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2009)
Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial
Ali S. Taha et al.
LANCET (2009)
Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials
Michelle L. O'Donoghue et al.
LANCET (2009)
Cytochrome P-450 Polymorphisms and Response to Clopidogrel.
Jessica L. Mega et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Genetic Determinants of Response to Clopidogrel and Cardiovascular Events.
Tabassome Simon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Gastrointestinal bleeding in patients receiving a combination of aspirin, clopidogrel, and enoxaparin in acute coronary syndrome
Fook-Hong Ng et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2008)
Cytochrome P450 and chemical toxicology
F. Peter Guengerich
CHEMICAL RESEARCH IN TOXICOLOGY (2008)
Proton pump inhibitors - Do differences in pharmacokinetics translate into differences in clinical outcomes?
Kwong Ming Fock et al.
CLINICAL PHARMACOKINETICS (2008)
The biotransformation of prasugrel, a new thienopyridine prodrug, by the human carboxylesterases 1 and 2
Eric T. Williams et al.
DRUG METABOLISM AND DISPOSITION (2008)
Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel
David S. Small et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin
Martine Gilard et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2008)
The association of cigarette smoking with enhanced platelet inhibition by clopidogrel
Kevin P. Bliden et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2008)
ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents
Deepak L. Bhatt et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2008)
The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics in an active metabolite of clopidogrel in healthy subjects
K. Umemura et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2008)
Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention - The prasugrel in comparison to clopidogrel for inhibition of platelet activation and aggregation-thrombolysis in myocardial infarction 44 trial
Stephen D. Wiviott et al.
CIRCULATION (2007)
Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel
J. T. Brandt et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2007)
Prasugrel versus clopidogrel in patients with acute coronary syndromes
Stephen D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Influence of CYP2C19 and CYP3A4 gene polymorphisms on clopidogrel responsiveness in healthy subjects
P. Fontana et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2007)
Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently
N. A. Farid et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
CYP2C19 pharmacogenomics associated with therapy of Helicobacter pylori infection and gastro-esophageal reflux diseases with a proton pump inhibitor
Takahisa Furuta et al.
PHARMACOGENOMICS (2007)
Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement
Willibald Hochholzer et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2006)
Cytochrorne P4502C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects
Jean-Sebastien Hulot et al.
BLOOD (2006)
ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention)
SC Smith et al.
CIRCULATION (2006)
Pharmacokinetic drug interaction profiles of proton pump inhibitors
Henning Blume et al.
DRUG SAFETY (2006)
The chemically elegant proton pump inhibitors
Victoria F. Roche
AMERICAN JOURNAL OF PHARMACEUTICAL EDUCATION (2006)
Clopidogrel effect on platelet REactivity in patients with stent thrombosis - Results of the CREST study
PA Gurbel et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2005)
Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities
XQ Li et al.
DRUG METABOLISM AND DISPOSITION (2004)
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction
S Matetzky et al.
CIRCULATION (2004)
Review article: relationship between the metabolism and efficacy of proton pump inhibitors - focus on rabeprazole
J Horn
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2004)
Resistance to thienopyridines: Clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation
P Barragan et al.
CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS (2003)
The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin
TA Clarke et al.
DRUG METABOLISM AND DISPOSITION (2003)
The cytochrome P450 superfamily: Biochemistry, evolution and drug metabolism in humans
PB Danielson
CURRENT DRUG METABOLISM (2002)
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention - A randomized controlled trial
SR Steinhubl et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2002)
Clinical significance of the cytochrome P4502C19 genetic polymorphism
Z Desta et al.
CLINICAL PHARMACOKINETICS (2002)
Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes
Y Horai et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2001)
Pantoprazole: A new proton pump inhibitor
PW Jungnickel
CLINICAL THERAPEUTICS (2000)
The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties
A Sugidachi et al.
BRITISH JOURNAL OF PHARMACOLOGY (2000)
Share Paper
